IL2 and neoplasm: Serial imaging in 11 patients with 30 tumor lesions showed a decrease in [18F]FB-IL2 tumor uptake from SUVmax 1.8 (IQR: 1.7–2.1) at baseline to SUVmax 1.7 (IQR: 1.4–2.1) during treatment (P = 0.043).